Evidence of a role for activation of Wnt/beta-catenin signaling in the resistance of plasma cells to lenalidomide. - Wikidata - awgldk - TriplyDB

Evidence of a role for activation of Wnt/beta-catenin signaling in the resistance of plasma cells to lenalidomide.

Evidence of a role for activation of Wnt/beta-catenin signaling in the resistance of plasma cells to lenalidomide.

http://www.wikidata.org/entity/Q34719436

about

An integrative genomic analysis revealed the relevance of microRNA and gene expression for drug-resistance in human breast cancer cells Cancer-selective targeting of the NF-κB survival pathway with GADD45β/MKK7 inhibitors What is the functional role of the thalidomide binding protein cereblon?Novel agents for multiple myeloma to overcome resistance in phase III clinical trials Non-Darwinian dynamics in therapy-induced cancer drug resistance.Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms.Inhibition of the MDM2 E3 Ligase induces apoptosis and autophagy in wild-type and mutant p53 models of multiple myeloma, and acts synergistically with ABT-737 Phase II study of the c-MET inhibitor tivantinib (ARQ 197) in patients with relapsed or relapsed/refractory multiple myeloma.Expression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma.Fibroblast activation protein protects bortezomib-induced apoptosis in multiple myeloma cells through β-catenin signaling pathway Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide.Crosstalk between microRNA30a/b/c/d/e-5p and the canonical Wnt pathway: implications for multiple myeloma therapy Novel approaches to treatment of double-refractory multiple myeloma.Anti-β₂M monoclonal antibodies kill myeloma cells via cell- and complement-mediated cytotoxicity.Mechanism of immunomodulatory drugs' action in the treatment of multiple myeloma.Targeting the pro-survival protein MET with tivantinib (ARQ 197) inhibits growth of multiple myeloma cells.Ribosomal Protein Mutations Result in Constitutive p53 Protein Degradation through Impairment of the AKT Pathway Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4.Polyphyllin I induces cell cycle arrest and apoptosis in human myeloma cells via modulating β-catenin signaling pathway.Simultaneous Analysis of Wnt and NF-κB Signaling Pathways in Doxorubicin Sensitive and Methotrexate Resistant PLC/ PRF/5 Cells Pomalidomide in combination with dexamethasone results in synergistic anti-tumour responses in pre-clinical models of lenalidomide-resistant multiple myeloma.Wnt3a: functions and implications in cancer.CDK inhibitors upregulate BH3-only proteins to sensitize human myeloma cells to BH3 mimetic therapies.Targeting the Spleen Tyrosine Kinase with Fostamatinib as a Strategy against Waldenström Macroglobulinemia.Tight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma via EGFR/JAK1/STAT3 Signaling.Evidence of a role for CD44 and cell adhesion in mediating resistance to lenalidomide in multiple myeloma: therapeutic implications.Targeting MET kinase with the small-molecule inhibitor amuvatinib induces cytotoxicity in primary myeloma cells and cell lines.Secreted frizzled related protein 1 modulates taxane resistance of human lung adenocarcinoma.Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma.Lenalidomide in lymphomas and chronic lymphocytic leukemia.Wnt/β-catenin signaling pathway may regulate the expression of angiogenic growth factors in hepatocellular carcinoma.RNA Polymerase I Inhibition with CX-5461 as a Novel Therapeutic Strategy to Target MYC in Multiple Myeloma.Multiple myeloma cells' capacity to decompose H2O2 determines lenalidomide sensitivity.Targeting of BMI-1 with PTC-209 shows potent anti-myeloma activity and impairs the tumour microenvironment.In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone.β-catenin is dynamically stored and cleared in multiple myeloma by the proteasome-aggresome-autophagosome-lysosome pathway.Targeting executioner procaspase-3 with the procaspase-activating compound B-PAC-1 induces apoptosis in multiple myeloma cells.Lenalidomide increases human dendritic cell maturation in multiple myeloma patients targeting monocyte differentiation and modulating mesenchymal stromal cell inhibitory properties MUC1-C is a target in lenalidomide resistant multiple myeloma.Truncated protein tyrosine phosphatase receptor type O suppresses AKT signaling through IQ motif containing GTPase activating protein 1 and confers sensitivity to bortezomib in multiple myeloma.

P2860

Q21245772-1073B292-1182-415E-945B-96D6A0A58E4E Q24305602-219A9308-3870-45D8-A563-50926D9ADA9E Q24635072-17BF76E8-4679-45AB-A0EB-0CDEC05DFB34 Q26822754-AAF44C8F-8C50-4BEC-AFDB-C61722312F71 Q27324745-314100F5-6178-40F5-8C32-C0666C6F8E20 Q27692033-F24ED2CB-CD58-4376-9C14-E12CFD1A275D Q28542684-A784C5F7-C423-40E5-A8C7-96F108D0A429 Q33168449-0406DC53-77FE-46F6-B4D4-F6C287B665CF Q33846806-38362C29-2999-4039-9ABF-181843FB8103 Q34036138-B6CC9132-87CC-4142-8666-8ADA1813E13E Q34210005-985D59BA-2827-436D-9F9B-B40210DEFB5B Q34287900-8F6C5A7B-D16D-483A-82E9-201EA87AB8BF Q34347172-A4B3944F-1D27-4FD7-B72D-B828DD2B673B Q34502870-613190DB-5FB2-491C-B086-BC8A103498D1 Q35171777-23DC2340-4297-41F7-8601-4E70C635F3E1 Q35214544-D40CE210-274E-4737-AC07-C2765D851C09 Q35680232-83E036D8-EF91-4B90-B760-50CEF7216B29 Q35796527-AF693D14-7773-4486-8B58-44BED25E9EFE Q35907565-2B0780B8-4AA9-48AF-9C74-2D5254B5ABC5 Q35919285-CEACF525-0F7D-4E5B-B50A-D83866BB02D6 Q35935794-AEA8EA9B-9ED0-4DEB-B31D-39FD58B543C0 Q36121065-D7978E08-55DC-4F37-BE6C-639D1EEC2FD5 Q36170136-03FF2D7C-BFA6-452E-AFAE-BDA1666AD37A Q36533710-1FC2EC64-63D5-4344-B325-22733B9257B9 Q37171812-41ABB8EB-6996-4099-A401-1764AD7E5E67 Q37417591-517F0C67-622D-4B68-BC76-A72748746E81 Q37427337-B13A9D44-6910-4D2B-A818-138356073045 Q37728993-B9216290-2149-46A9-9045-A267B04061B0 Q38042444-441037A7-276E-4410-A1DB-BEF2A5217E93 Q38077277-3E0D0165-880B-46A1-BC92-DFD7B7C80CBF Q38374930-4D14385C-3791-48D6-80C2-60402E57495D Q38709232-D68BE515-0072-4899-888F-9BD467B44DBE Q38724074-DF751BEF-9FD0-454F-A549-0A5B6E52B793 Q38748203-69AF4F1C-4AE5-4C5B-81B2-BD0747534E18 Q38968027-EE988AE6-A7B5-4E53-BD9E-A276C74AA7FE Q40094733-CDDA2345-84CA-4C8A-BF13-288DC6D0B159 Q40643079-402058D4-C91F-4964-BC74-F3731556D1C5 Q41593035-109D52D2-277A-4D52-88A7-D19242980E5E Q46345708-71A51006-0281-460A-9A56-3898FEEEF8BF Q49166966-9926A2EA-F782-44CC-8833-9A145AF48D59

P2860

Evidence of a role for activation of Wnt/beta-catenin signaling in the resistance of plasma cells to lenalidomide.

http://www.wikidata.org/entity/Q34719436

description

2010 nî lūn-bûn

@nan

2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Evidence of a role for activat ...... plasma cells to lenalidomide.

@ast

Evidence of a role for activat ...... plasma cells to lenalidomide.

@en

Evidence of a role for activat ...... plasma cells to lenalidomide.

@nl

type

label

Evidence of a role for activat ...... plasma cells to lenalidomide.

@ast

Evidence of a role for activat ...... plasma cells to lenalidomide.

@en

Evidence of a role for activat ...... plasma cells to lenalidomide.

@nl

prefLabel

Evidence of a role for activat ...... plasma cells to lenalidomide.

@ast

Evidence of a role for activat ...... plasma cells to lenalidomide.

@en

Evidence of a role for activat ...... plasma cells to lenalidomide.

@nl

P1433

Q34719436-5669174F-58D3-4700-A2EC-7AB553CBEF28

P1476

Q34719436-93115459-BD55-408E-B675-5FC57C1C5763

P2093

Q34719436-295952A8-CF3F-45B6-9ADB-DD65641C1983

Q34719436-4528B25B-8BA3-4E84-9D27-F09B3CC7F5B4

Q34719436-61568207-DE50-4310-83A2-37260BB2296E

Q34719436-C05AA8F8-2185-4E29-9AC1-D692734BD885

Q34719436-C71A2839-7B8E-4A01-BC89-A69529A6D504

Q34719436-E2E0ECAD-52F9-46E4-A1D3-9F428DAF42B5

Q34719436-FAB5B419-C2E4-47CB-A84E-E4F2E61BF365

Q34719436-FBE8A139-CCD2-404F-9960-7FA5A3E7F036

P2860

Q34719436-07FF7E50-98E9-4273-9238-5C0573B922C4

Q34719436-0C7ECD6F-0597-4285-BAB8-7A074B90EE20

Q34719436-0E1540B4-FEBC-42CA-9211-EB40F1A40C5B

Q34719436-0EF3AD4E-38E1-4BA2-B083-70CC5014815F

Q34719436-14739A25-EC31-41C9-A908-78AB43EBEED9

Q34719436-1AAB8406-281A-4F93-ACDF-1DB8E51811F6

Q34719436-1B05B4A8-8728-48F6-A904-2CEB3EE58861

Q34719436-20E2C97C-FD70-4746-AA6B-4305D35FE853

Q34719436-25EECF50-3DAC-4B6A-83E6-6AF4E998D5BE

Q34719436-2C5EBD64-3279-4E45-810C-96CC317FFA42

P304

Q34719436-15044263-C707-482D-BE16-DED3F8FBDE8F

P31

Q34719436-2ED66709-F4AA-49B6-9A6A-A687B4348855

P356

Q34719436-36B8D6EE-C9D1-42D7-917F-6E2D506AB24F

P407

Q34719436-4007B89A-A697-4289-854F-5DB2E5E856D3

P433

Q34719436-B420684B-6173-4B44-AA11-528C27A3AD67

P478

Q34719436-526EF510-303C-4C88-941D-8BF3E9F22B72

P50

Q34719436-0604D0AB-3295-49B2-A12E-D31E21D3B49E

P577

Q34719436-5B070134-51BB-4A44-B786-AA213B6FA294

P5875

Q34719436-EC66E8BB-5A0C-4CF3-9FA0-AD34B1C35558

P698

Q34719436-0314F943-07FB-4A1C-8B7C-103CD07E5A6D

P932

Q34719436-3778D4A9-20F2-4BF4-833A-648342EF83BC

P356

JBC.M110.180208

P1433

Journal of Biological Chemistry

P1476

Evidence of a role for activat ...... plasma cells to lenalidomide.

@en

P2093

Chad C Bjorklund

http://www.w3.org/2001/XMLSchema#string

Deborah J Kuhn

http://www.w3.org/2001/XMLSchema#string

Jatin J Shah

http://www.w3.org/2001/XMLSchema#string

Michael Wang

http://www.w3.org/2001/XMLSchema#string

R Eric Davis

http://www.w3.org/2001/XMLSchema#string

Steven M Kornblau

http://www.w3.org/2001/XMLSchema#string

Wencai Ma

http://www.w3.org/2001/XMLSchema#string

Zhi-Qiang Wang

http://www.w3.org/2001/XMLSchema#string

P2860

Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A

Glycogen synthase kinase 3: more than a namesake

The Wnt receptor FZD1 mediates chemoresistance in neuroblastoma through activation of the Wnt/beta-catenin pathway

Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma

Wnt/beta-catenin signaling: components, mechanisms, and diseases

Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.

Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma.

P304

11009-11020

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1074/JBC.M110.180208

http://www.w3.org/2001/XMLSchema#string

P407

P433

13

http://www.w3.org/2001/XMLSchema#string

P478

286

http://www.w3.org/2001/XMLSchema#string

P50

Robert Z Orlowski

P577

2010-12-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49712660

http://www.w3.org/2001/XMLSchema#string

P698

21189262

http://www.w3.org/2001/XMLSchema#string

P932

3064156

http://www.w3.org/2001/XMLSchema#string